Linc AB (LINC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Linc AB (LINC) has a cash flow conversion efficiency ratio of 0.003x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr13.90 Million ≈ $1.50 Million USD) by net assets (Skr4.43 Billion ≈ $476.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Linc AB - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Linc AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Linc AB (LINC) total liabilities for a breakdown of total debt and financial obligations.
Linc AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Linc AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Daewon Cable Co. Ltd. Preference Shares
KO:006345
|
-0.036x |
|
Zinzino AB Series B
ST:ZZ-B
|
0.236x |
|
Dalian Thermal Power Co Ltd
SHG:600719
|
-0.345x |
|
Liaoning He Eye Hospital Group Co. LTD.
SHE:301103
|
N/A |
|
Ion Beam Applications SA
BR:IBAB
|
-0.314x |
|
Yaxing Chem
SHG:600319
|
-0.077x |
|
Importadora y Exportadora de la Patagonia SA
BA:PATA
|
0.024x |
|
Larvotto Resources Ltd
AU:LRV
|
-0.138x |
Annual Cash Flow Conversion Efficiency for Linc AB (2018–2025)
The table below shows the annual cash flow conversion efficiency of Linc AB from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Linc AB (LINC) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr4.43 Billion ≈ $476.85 Million |
Skr4.25 Million ≈ $457.91K |
0.001x | -84.37% |
| 2024-12-31 | Skr4.83 Billion ≈ $519.86 Million |
Skr29.68 Million ≈ $3.19 Million |
0.006x | +126.91% |
| 2023-12-31 | Skr3.53 Billion ≈ $379.78 Million |
Skr-80.57 Million ≈ $-8.67 Million |
-0.023x | +70.88% |
| 2022-12-31 | Skr2.91 Billion ≈ $313.12 Million |
Skr-228.15 Million ≈ $-24.55 Million |
-0.078x | +19.49% |
| 2021-12-31 | Skr3.63 Billion ≈ $390.96 Million |
Skr-353.84 Million ≈ $-38.08 Million |
-0.097x | -1560.96% |
| 2020-12-31 | Skr2.49 Billion ≈ $268.42 Million |
Skr-14.63 Million ≈ $-1.57 Million |
-0.006x | -929.67% |
| 2019-12-31 | Skr1.66 Billion ≈ $178.75 Million |
Skr1.17 Million ≈ $126.34K |
0.001x | +103.83% |
| 2018-12-31 | Skr1.06 Billion ≈ $114.60 Million |
Skr-19.65 Million ≈ $-2.11 Million |
-0.018x | -- |
About Linc AB
Linc AB is a private equity and venture capital firm, specializing in early and mature stage investments in pharmaceutical, life-science and med-tech companies. It prefers to invest in drug development usually take place at an early stage, while investments in medical technology are made in more mature businesses. The investments are made in both private and public companies and in research and o… Read more